Back to top
more

TransMedics Group (TMDX)

(Real Time Quote from BATS)

$84.55 USD

84.55
262,519

-0.95 (-1.11%)

Updated Nov 8, 2024 10:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?

by Zacks Equity Research

Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.

NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up

by Zacks Equity Research

NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.

Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches

by Zacks Equity Research

Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.

Haemonetics (HAE) Set to Launch VASCADE MVP XL in US

by Zacks Equity Research

Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.

Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.

Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial

by Zacks Equity Research

Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.

Why You Should Add Exact Sciences (EXAS) to Your Portfolio

by Zacks Equity Research

Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.

Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook

by Zacks Equity Research

Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.

Should Quest Diagnostics (DGX) be in Your Portfolio Now?

by Zacks Equity Research

Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.

TransMedics (TMDX) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Can TransMedics (TMDX) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

New Strong Buy Stocks for August 2nd

by Zacks Equity Research

SVM, IBCP, TMDX, WT and YELP have been added to the Zacks Rank #1 (Strong Buy) List on August 2, 2024.

Compared to Estimates, TransMedics (TMDX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of 66.67% and 15.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings

by Zacks Equity Research

Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Hims & Hers Health, Inc. (HIMS) and TransMedics (TMDX) have performed compared to their sector so far this year.

Here's How STERIS (STE) is Placed Ahead of Q1 Earnings

by Zacks Equity Research

STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.

Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings

by Zacks Equity Research

IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.

TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice

by Zacks Equity Research

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.